Trial Profile
A Phase One, Open-Label Single-Radiolabeled Dose Study To Investigate The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary)
- Indications Colorectal cancer; Endometrial cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 Aug 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 May 2014 New trial record